BERKELEY, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced Tom Klein has joined the Company as Chief Commercial Officer, a newly created position reporting to John Varian, XOMA's Chief Executive Officer. Mr. Klein brings over 25 years of successful brand commercialization leadership, with an expertise in commercializing biologic products to medical specialists. Mr. Klein joins XOMA from Genentech, where he was Vice President, Business Unit Head Virology and Specialty Care.
"We created an executive-level position for commercial operations for two reasons. First, with the gevokizumab Phase 3 NIU program expected to begin delivering primary endpoint results at the end of this year and into the first half of next year, we are at the point where we are ready to begin building XOMA's launch strategy and commercialization plans. The importance of creating the sales and marketing plan for our first XOMA-developed product cannot be underestimated. We will build on Tom's vast experience to develop a launch program that maximizes the commercial potential of gevokizumab in the U.S. and that we can successfully execute from the day we hopefully receive BLA approval," stated Mr. Varian. "The second reason for creating a CCO position was to fully integrate market analyses into our clinical development decisions. The ability to foresee the commercial landscape of a clinical candidate early in the process is crucial to maximizing its commercial potential. Tom will draw on his years of experience and his vast network to provide our team with the most accurate information that will guide our second, third and fourth gevokizumab indications. The team and I are looking forward to working closely with Tom to ensure gevokizumab is a commercial success in the United States."
During his tenure with Genentech, Mr. Klein worked closely with both the Roche and Genentech teams to develop and execute commercial integration plans that met the needs of each company in their respective territories. Mr. Klein joined Genentech from Roche, where he had direct oversight over the Roche Hepatology and HIV Sales and Marketing teams and was responsible for ensuring affiliate and global strategic alignment. Prior to his 12 years with Roche, Mr. Klein spent 11 years with Westwood-Squibb/Bristol Myers-Squibb in a several sales and product management roles. Mr. Klein has launch experience in both the specialty and primary care markets, most recently with Boniva® (ibandronate sodium) for the treatment of osteoporosis in postmenopausal women. He also has been responsible for the category leading growth of Pegasys® (peginterferon alpha-2a) in HCV and market leadership of Pulmozyme® (dornase alfa) in cystic fibrosis, a rare disease area. Mr. Klein has a BA, Marketing, from Pennsylvania State University and an MBA, Management from Temple University.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV